NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

Performance characteristics of rDNA and synthetic peptide-based combined HIV 1 and 2 EIA's for detection of antibodies in clinical specimens.

Galli RA, Fearon M, Castriciano S, Mahony J, Chernesky M; International Conference on AIDS.

Int Conf AIDS. 1992 Jul 19-24; 8: 159 (abstract no. PuC 8036).

Ontario Ministry of Health Laboratory, Canada.

OBJECTIVES: A collaborative study was conducted in 2 Canadian laboratories to measure the performance characteristics of a recombinant HIV-1/HIV-2 EIA (Abbott Laboratories, North Chicago, USA) and a synthetic peptide-based HIV-1/HIV-2 EIA (IAF Biochem, Montreal, PQ., Canada). METHODS: Serum/plasma samples originally obtained for routine clinical testing were used in this study. Testing of serum panels was performed on both assays and the Western Blot (WB) was used as the gold standard confirmatory test for all specimens repeatedly reactive by either EIA method. A total of 1046 confirmed HIV-1 specimens, 10 confirmed HIV-2 specimens, 1085 prospective specimens from current submissions and 204 sera from 84 known seroconversion cases were included in this study. p24 Antigen (Abbott), RIPA and immunoglobulin class analyses were also conducted on selected samples. RESULTS: There was 100% agreement between both assays and the WB for the confirmed 1046 HIV 1 and 10 HIV-2 panels. Of the 1085 prospective samples, 38 were repeatedly reactive (RR) by both EIA's and WB, 1 was RR by both EIA's but was WB indeterminate, 9 were RR by IAF only and 2 were RR by Abbott only. Of the 204 seroconversion specimens (SC), 194 were RR by both EIA's and WB and 10 were RR by Abbott only. These 10 were initial specimens of a SC and 7 were found to be p24 Antigen reactive. Analysis of the anti-env antibody class in 3 of these SC samples showed 1 to be IgM only and 2 to be IgM and IgG. CONCLUSIONS: The recombinant Abbott HIVAB HIV-1/2 EIA and the peptide IAF Biochem DETECT-HIV assays have a high degree of sensitivity and specificity for detection of antibodies in clinical specimens. Both assays are capable of detecting early antibodies, but there is evidence that the Abbott assay had enhanced sensitivity toward IgM detection.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Acquired Immunodeficiency Syndrome
  • Animals
  • Antibodies
  • Blotting, Western
  • Canada
  • Chicago
  • DNA, Recombinant
  • DNA, Ribosomal
  • Equine Infectious Anemia
  • Genes, env
  • HIV Antibodies
  • HIV Infections
  • HIV Seropositivity
  • HIV-1
  • HIV-2
  • Immunoenzyme Techniques
  • Indicators and Reagents
  • Longitudinal Studies
  • Reagent Kits, Diagnostic
  • Sensitivity and Specificity
  • genetics
Other ID:
  • 92403716
UI: 102201430

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov